新发心房颤动

National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management. April 2021 [internet publication].全文

Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014 Jun 26;370(26):2467-77.全文  摘要

Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014 Jun 26;370(26):2478-86.全文  摘要

Gorenek B, Pelliccia A, Benjamin EJ, et al. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Europace. 2017 Feb 1;19(2):190-225.全文  摘要

Lilli A, Di Cori A, Zacà V. Thromboembolic risk and effect of oral anticoagulation according to atrial fibrillation patterns: a systematic review and meta-analysis. Clin Cardiol. 2017 Sep;40(9):641-7.全文  摘要

O'Dell KM, Igawa D, Hsin J. New oral anticoagulants for atrial fibrillation: a review of clinical trials. Clin Ther. 2012 Apr;34(4):894-901. 摘要

Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012 Aug 1;110(3):453-60.全文  摘要

National Institute for Health and Care Excellence. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. 15 March 2012 [internet publication].全文

1. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76.全文  摘要

2. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016 Nov;18(11):1609-78.全文  摘要

3. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation. 2014 Feb 25;129(8):837-47.全文  摘要

4. Sudlow M, Thomson R, Thwaites B, et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet. 1998 Oct 10;352(9135):1167-71. 摘要

5. Lip GY, Golding DJ, Nazir M, et al. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract. 1997 May;47(418):285-9.全文  摘要

6. Adderley NJ, Ryan R, Nirantharakumar K, et al. Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016. Heart. 2019 Jan;105(1):27-33. 摘要

7. Lip GY, Tean KN, Dunn FG. Treatment of atrial fibrillation in a district general hospital. Br Heart J. 1994 Jan;71(1):92-5.全文  摘要

8. Zarifis J, Beevers G, Lip GY. Acute admissions with atrial fibrillation in a British multiracial hospital population. Br J Clin Pract. 1997 Mar;51(2):91-6. 摘要

9. National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management. April 2021 [internet publication].全文

10. Lip GYH, Apostolakis S. Atrial fibrillation (acute onset). BMJ Clin Evid. 2014 Nov 27;2014.全文  摘要

11. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke, results from a population-based study. Stroke. 2005 Jun;36(6):1115-9.全文  摘要

12. Paciaroni M, Agnelli G, Caso V, et al. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemost. 2005 Jun;3(6):1218-23.全文  摘要

13. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014 Jun 26;370(26):2467-77.全文  摘要

14. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014 Jun 26;370(26):2478-86.全文  摘要

15. Wong CK, White HD, Wilcox RG, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J. 2000 Dec;140(6):878-85. 摘要

16. Asanin M, Perunicic J, Mrdovic I, et al. Prognostic significance of new atrial fibrillation and its relation to heart failure following acute myocardial infarction. Eur J Heart Fail. 2005 Jun;7(4):671-6.全文  摘要

17. Mentz RJ, Chung MJ, Gheorghiade M, et al. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. Am Heart J. 2012 Dec;164(6):884-92;e2.全文  摘要

18. Falk RH. Atrial fibrillation. N Engl J Med. 2001 Apr 5;344(14):1067-78. 摘要

19. Mukamal KJ, Tolstrup JS, Friberg J, et al. Alcohol consumption and risk of atrial fibrillation in men and women. Circulation. 2005 Sep 20;112(12):1736-42.全文  摘要

20. Agarwal A, York M, Kantharia BK, et al. Atrial fibrillation: modern concepts and management. Annu Rev Med. 2005;56:475-94. 摘要

21. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998 Sep 3;339(10):659-66.全文  摘要

22. Peters NS, Schilling RJ, Kanagaratnam P, et al. Atrial fibrillation: strategies to control, combat, and cure. Lancet. 2002 Feb 16;359(9306):593-603. 摘要

23. Kochiadakis GE, Skalidis EI, Kalebubas MD, et al. Effect of acute atrial fibrillation on phasic coronary blood flow pattern and flow reserve in humans. Eur Heart J. 2002 May;23(9):734-41. 摘要

24. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994 Mar 16;271(11):840-4. 摘要

25. Lip GY, Beevers DG, Singh SP, et al. ABC of atrial fibrillation: etiology, pathophysiology, and clinical features. BMJ. 1995 Nov 25;311(7017):1425-8.全文  摘要

26. Wang Q, Guo Y, Wu C, et al. Smoking as a risk factor for the occurrence of atrial fibrillation in men versus women: a meta-analysis of prospective cohort studies. Heart Lung Circ. 2018 Jan;27(1):58-65. 摘要

27. Upala S, Shahnawaz A, Sanguankeo A. Psoriasis increases risk of new-onset atrial fibrillation: a systematic review and meta-analysis of prospective observational studies. J Dermatolog Treat. 2017 Aug;28(5):406-10. 摘要

28. Ungprasert P, Srivali N, Kittanamongkolchai W. Risk of incident atrial fibrillation in patients with rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis. 2017 Apr;20(4):434-41. 摘要

29. Gorenek B, Pelliccia A, Benjamin EJ, et al. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Europace. 2017 Feb 1;19(2):190-225.全文  摘要

30. Lavie CJ, Pandey A, Lau DH, et al. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. J Am Coll Cardiol. 2017 Oct 17;70(16):2022-35.全文  摘要

31. Middeldorp ME, Pathak RK, Meredith M, et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on atrial fibrillation: the REVERSE-AF study. Europace. 2018 Dec 1;20(12):1929-35.全文  摘要

32. Baumgartner C, da Costa BR, Collet TH, et al; Thyroid Studies Collaboration. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation. 2017 Nov 28;136(22):2100-16.全文  摘要

33. Hijazi Z, Siegbahn A, Andersson U, et al; ARISTOTLE Investigators. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Feb 11;129(6):625-34.全文  摘要

34. Kotecha D, Mohamed M, Shantsila E, et al. Is echocardiography valid and reproducible in patients with atrial fibrillation? A systematic review. Europace. 2017 Sep 1;19(9):1427-38.全文  摘要

35. Fauchier L, Clementy N, Pelade C, et al. Patients with ischemic stroke and incident atrial fibrillation: a nationwide cohort study. Stroke. 2015 Sep;46(9):2432-7.全文  摘要

36. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70.全文  摘要

37. Yarmohammadi H, Varr BC, Puwanant S, et al. Role of CHADS2 score in evaluation of thromboembolic risk and mortality in patients with atrial fibrillation undergoing direct current cardioversion (from the ACUTE Trial Substudy). Am J Cardiol. 2012 Jul 15;110(2):222-6.全文  摘要

38. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006 Mar;151(3):713-9. 摘要

39. Saliba W, Gronich N, Barnett-Griness O, et al. Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study. Am J Med. 2016 Aug;129(8):843-9.全文  摘要

40. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100. 摘要

41. Jonas DE, Kahwati LC, Yun JDY, et al. Screening for atrial fibrillation with electrocardiography: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018 Aug 7;320(5):485-98.全文  摘要

42. US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for atrial fibrillation with electrocardiography: US Preventive Services Task Force recommendation statement. JAMA. 2018 Aug 7;320(5):478-84.全文  摘要

43. Taggar JS, Coleman T, Lewis S, et al. Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: a systematic review and meta-analysis. Eur J Prev Cardiol. 2016 Aug;23(12):1330-8.全文  摘要

44. Gillis AM, Morck M. Atrial fibrillation after DDDR pacemaker implantation. J Cardiovasc Electrophysiol. 2002 Jun;13(6):542-7. 摘要

45. Kanji S, Stewart R, Fergusson DA, et al. Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized controlled trials. Crit Care Med. 2008 May;36(5):1620-4. 摘要

46. Okcun B, Yigit Z, Yildiz A, et al. What should be the primary treatment in atrial fibrillation: ventricular rate control or sinus rhythm control with long-term anticoagulation? J Int Med Res. 2009 Mar-Apr;37(2):464-71.全文  摘要

47. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. [Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.]全文  摘要

48. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019 Jul 9;140(2):e125-51.全文  摘要

49. Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J. 2016 Feb 16;37(20):1591-602.全文  摘要

50. Lilli A, Di Cori A, Zacà V. Thromboembolic risk and effect of oral anticoagulation according to atrial fibrillation patterns: a systematic review and meta-analysis. Clin Cardiol. 2017 Sep;40(9):641-7.全文  摘要

51. Lopes RD, Rordorf R, De Ferrari GM, et al; ARISTOTLE Committees and Investigators. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018 Mar 13;71(10):1063-74.全文  摘要

52. Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996 Mar 15;93(6):1262-77.全文  摘要

53. Roy D, Pratt CM, Torp-Pedersen C, et al; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008 Mar 25;117(12):1518-25.全文  摘要

54. Kowey PR, Dorian P, Mitchell LB, et al; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009 Dec;2(6):652-9.全文  摘要

55. Camm AJ, Capucci A, Hohnloser SH, et al; AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011 Jan 18;57(3):313-21.全文  摘要

56. Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007 Sep 6;357(10):987-99.全文  摘要

57. Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605. 摘要

58. Hohnloser SH, Crijns HJ, van Eickels M, et al; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009 Feb 12;360(7):668-78.全文  摘要

59. National Institute for Health and Care Excellence. Dronedarone for the treatment of non-permanent atrial fibrillation. 1 December 2012 [internet publication].全文

60. National Institute for Health and Care Excellence. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. 23 May 2012 [internet publication].全文

61. O'Dell KM, Igawa D, Hsin J. New oral anticoagulants for atrial fibrillation: a review of clinical trials. Clin Ther. 2012 Apr;34(4):894-901. 摘要

62. Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012 Aug 1;110(3):453-60.全文  摘要

63. National Institute for Health and Care Excellence. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. 15 March 2012 [internet publication].全文

64. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91.全文  摘要

65. Halperin JL, Hankey GJ, Wojdyla DM, et al; ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014 Jul 8;130(2):138-46.全文  摘要

66. Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92.全文  摘要

67. Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104.全文  摘要

68. Caldeira D, Rodrigues FB, Barra M, et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart. 2015 Aug;101(15):1204-11. 摘要

69. Sharma M, Cornelius VR, Patel JP, et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015 Jul 21;132(3):194-204.全文  摘要

70. Del-Carpio Munoz F, Gharacholou SM, Munger TM, et al. Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation. Am J Cardiol. 2016 Jan 1;117(1):69-75. 摘要

71. Gallego P, Roldán V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014 Nov;127(11):1083-8.全文  摘要

72. Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014 Sep;146(3):719-26. 摘要

73. Xanthos T, Prapa V, Papadimitriou D, et al. Comparative study of intravenous amiodarone and procainamide in the treatment of atrial fibrillation of recent onset. Minerva Cardioangiol. 2007 Aug;55(4):433-41. 摘要

74. Heldal M, Atar D. Pharmacological conversion of recent-onset atrial fibrillation: a systematic review. Scand Cardiovasc J Suppl. 2013 Feb;47(1):2-10. 摘要

75. Kochiadakis GE, Igoumenidis NE, Hamilos ME, et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J Cardiol. 2007 Jun 15;99(12):1721-5.全文  摘要

76. Xanthos T, Bassiakou E, Vlachos IS, et al. Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration. Int J Cardiol. 2007 Oct 18;121(3):291-5. 摘要

77. Markey GC, Salter N, Ryan J. Intravenous flecainide for emergency department management of acute atrial fibrillation. J Emerg Med. 2018 Mar;54(3):320-27. 摘要

78. Torp-Pedersen C, Raev DH, Dickinson G, et al. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. Circ Arrhythm Electrophysiol. 2011 Oct;4(5):637-43.全文  摘要

79. Sorino M, Colonna P, De Luca L, et al. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study). J Cardiovasc Med (Hagerstown). 2007 Dec;8(12):1034-42. 摘要

80. Grönberg T, Hartikainen JE, Nuotio I, et al. Anticoagulation, CHA2DS2VASc score, and thromboembolic risk of cardioversion of acute atrial fibrillation (from the FinCV study). Am J Cardiol. 2016 Apr 15;117(8):1294-8. 摘要

81. Lip GY, Skjøth F, Rasmussen LH, et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015 Apr 14;65(14):1385-94.全文  摘要

82. Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015 Feb 24;65(7):635-42.全文  摘要

83. Joundi RA, Cipriano LE, Sposato LA, et al; Stroke Outcomes Research Working Group. Ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc score of 1: systematic review and meta-analysis. Stroke. 2016 May;47(5):1364-7.全文  摘要

84. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019 Jul 9;140(2):e125-51.全文  摘要

85. Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000 Nov;49(11):1033-46. 摘要

86. sanofi-aventis. Important information on the use of Multaq® (dronedarone). June 2009 [internet publication].全文

87. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-2687 (erratum in: N Engl J Med. 2010;363:1384).全文  摘要

88. Jabre P, Roger VL, Murad MH, et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation. 2011 Apr 19;123(15):1587-93.全文  摘要

89. Ruddox V, Sandven I, Munkhaugen J, et al. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol. 2017 Sep;24(14):1555-66.全文  摘要

90. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013 Nov 20;310(19):2050-60.全文  摘要